Literature DB >> 12074782

Testicular germ cell cancer despite previous local radiotherapy to the testis.

K-P Dieckmann1, H Lauke, U Michl, E Winter, V Loy.   

Abstract

BACKGROUND: Testicular intraepithelial neoplasia (TIN, also carcinoma in situ of the testis) is the uniform precursor of testicular germ cell cancer. Local radiotherapy to the testis with dosages of 18-20 Gy has been found to safely eradicate TIN and germ cells, too. Thus, the general assumption is that the development of invasive germ cell tumours can be prevented by this radiotherapy. PATIENTS AND METHODS: Herein, we report two patients with one-sided testicular tumour and biopsy-proven contralateral TIN. Both of them developed germ cell neoplasms in the remaining testis although local radiotherapy with 20 Gy had been applied to the testis.
RESULTS: One patient developed pure seminoma 7 years after completion of radiotherapy, the other developed a combined tumour consisting of embryonal carcinoma and seminoma after 5 years. Treatment consisted of orchiectomy in each of the cases. Histologically, both had TIN in the testicular tissue surrounding the new growths.
CONCLUSIONS: Pathogenetically, a small fraction of radioresistent TIN cells overcoming irradiation and progressing to full-blown germ cell cancer in the later course may be the histogenetic clue to explain these unexpected events. Other explanations, though less probable, could be technical radiotherapeutic failure due to targeting problems and a pre-existing radioresistent germ cell tumour in the irradiated testicle.

Entities:  

Mesh:

Year:  2002        PMID: 12074782     DOI: 10.1016/s0302-2838(02)00047-7

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

Review 1.  Microinvasive germ cell tumor of the testis.

Authors:  Finn Edler von Eyben; Grete Krag Jacobsen; Rolf Inge Skotheim
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

2.  Erratum to: Dendritic cells as therapeutic targets in neuroinflammation.

Authors:  Felix Luessi; Frauke Zipp; Esther Witsch
Journal:  Cell Mol Life Sci       Date:  2016-07       Impact factor: 9.261

3.  Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients.

Authors:  Rainer Souchon; Michael Hartmann; Susanne Krege; Anja Lorch; Frank Mayer; Maria De Santis; Silke Gillessen; Jörg Beyer; Richard Cathomas
Journal:  Strahlenther Onkol       Date:  2011-02-21       Impact factor: 3.621

Review 4.  Management of the contralateral testicle in patients with unilateral testicular cancer.

Authors:  Eugene K Lee; Jeffrey M Holzbeierlein
Journal:  World J Urol       Date:  2009-04-17       Impact factor: 4.226

5.  Young male patient with bilateral synchronous testicular germ cell tumour. Considerations for partial orchiectomy.

Authors:  Joan Manel Gasent Blesa; Juan Laforga Canales; Pedro Romero Pérez; Manuel Amat Cecilia; Francisco José Merenciano Cortina; Walid Rafie Macketli; Vicente Alberola Candel
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

6.  Partial orchiectomy and testis intratubular germ cell neoplasia: World literature review.

Authors:  Wassim M Bazzi; Omer A Raheem; Sean P Stroup; Christopher J Kane; Ithaar H Derweesh; Tracy M Downs
Journal:  Urol Ann       Date:  2011-09

7.  Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy.

Authors:  Ch Theodore; M J Terrier-Lacombe; A Laplanche; G Benoit; K Fizazi; O Stamerra; P Wibault
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

8.  Synchronous bilateral testis cancer: clinical and oncological management.

Authors:  Davide Campobasso; Stefania Ferretti; Antonio Frattini
Journal:  Contemp Oncol (Pozn)       Date:  2017-03-22

9.  Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group.

Authors:  J Classen; K Dieckmann; M Bamberg; R Souchon; S Kliesch; M Kuehn; V Loy
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.